Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The same preparation you do at home applies everywhere else
Gynecol Endocrinol 40(1):2328613
Trachootham et al., 2008
Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes
Close the package carefully after opening
US$ 26.98
US$ 27.48
US$ 24.18
US$ 28.37
US$ 27.58
US$ 24.66
US$ 24.97
US$ 25.91
US$ 29.21
